Xarelto® Reduces Symptomatic VTE And Death Following Knee Or Hip Replacement Surgery By More Than 50% Compared To Enoxaparin

Results from a pre-specified pooled analysis of the RECORD clinical trial program confirmed that the novel oral anticoagulant Xarelto® (rivaroxaban), taken as one tablet, once-daily, was superior to enoxaparin-based treatment regimens for the prevention of venous thromboembolism (VTE) after total knee or hip replacement surgery with low rates of major bleeding that were not statistically different from the comparator.

More: continued here

Filed under: Bones on December 11th, 2008